Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 5905 to 5914 of 5914 entries
Sorted by: Best Match Show Resources per page
The experiences and perceived health benefits of individuals with a disability participating in sport: A systematic review and narrative synthesis.

Disability and health journal

Aitchison B, Rushton AB, Martin P, Barr M, Soundy A, Heneghan NR.
PMID: 34238729
Disabil Health J. 2022 Jan;15(1):101164. doi: 10.1016/j.dhjo.2021.101164. Epub 2021 Jun 30.

BACKGROUND: Sports participation has many physical and mental health benefits for individuals with a disability including improved functionality and reduced anxiety, yet a large proportion of individuals with a disability are inactive.OBJECTIVE: To investigate the experiences and perceived health...

Cite
Aitchison B, Rushton AB, Martin P, et al. The experiences and perceived health benefits of individuals with a disability participating in sport: A systematic review and narrative synthesis. Disabil Health J. 2021;15(1):101164doi: 10.1016/j.dhjo.2021.101164.
Aitchison, B., Rushton, A. B., Martin, P., Barr, M., Soundy, A., & Heneghan, N. R. (2022). The experiences and perceived health benefits of individuals with a disability participating in sport: A systematic review and narrative synthesis. Disability and health journal, 15(1), 101164. https://doi.org/10.1016/j.dhjo.2021.101164
Aitchison, Beth, et al. "The experiences and perceived health benefits of individuals with a disability participating in sport: A systematic review and narrative synthesis." Disability and health journal vol. 15,1 (2022): 101164. doi: https://doi.org/10.1016/j.dhjo.2021.101164
Aitchison B, Rushton AB, Martin P, Barr M, Soundy A, Heneghan NR. The experiences and perceived health benefits of individuals with a disability participating in sport: A systematic review and narrative synthesis. Disabil Health J. 2022 Jan;15(1):101164. doi: 10.1016/j.dhjo.2021.101164. Epub 2021 Jun 30. PMID: 34238729.
Copy Download .nbib Format: NLM
Recognition of the antigen-presenting molecule MR1 by a Vδ3.

Proceedings of the National Academy of Sciences of the United States of America

Rice MT, von Borstel A, Chevour P, Awad W, Howson LJ, Littler DR, Gherardin NA, Le Nours J, Giles EM, Berry R, Godfrey DI, Davey MS, Rossjohn J, Gully BS.
PMID: 34845016
Proc Natl Acad Sci U S A. 2021 Dec 07;118(49). doi: 10.1073/pnas.2110288118.

Unlike conventional αβ T cells, γδ T cells typically recognize nonpeptide ligands independently of major histocompatibility complex (MHC) restriction. Accordingly, the γδ T cell receptor (TCR) can potentially recognize a wide array of ligands; however, few ligands have been...

Cite
Rice MT, von Borstel A, Chevour P, et al. Recognition of the antigen-presenting molecule MR1 by a Vδ3. Proc Natl Acad Sci U S A. 2021;118(49)doi: 10.1073/pnas.2110288118.
Rice, M. T., von Borstel, A., Chevour, P., Awad, W., Howson, L. J., Littler, D. R., Gherardin, N. A., Le Nours, J., Giles, E. M., Berry, R., Godfrey, D. I., Davey, M. S., Rossjohn, J., & Gully, B. S. (2021). Recognition of the antigen-presenting molecule MR1 by a Vδ3. Proceedings of the National Academy of Sciences of the United States of America, 118(49), . https://doi.org/10.1073/pnas.2110288118
Rice, Michael T, et al. "Recognition of the antigen-presenting molecule MR1 by a Vδ3." Proceedings of the National Academy of Sciences of the United States of America vol. 118,49 (2021). doi: https://doi.org/10.1073/pnas.2110288118
Rice MT, von Borstel A, Chevour P, Awad W, Howson LJ, Littler DR, Gherardin NA, Le Nours J, Giles EM, Berry R, Godfrey DI, Davey MS, Rossjohn J, Gully BS. Recognition of the antigen-presenting molecule MR1 by a Vδ3. Proc Natl Acad Sci U S A. 2021 Dec 07;118(49). doi: 10.1073/pnas.2110288118. PMID: 34845016; PMCID: PMC8694053.
Copy Download .nbib Format: NLM
Complement activation in IgA nephropathy.

Seminars in immunopathology

Medjeral-Thomas NR, Cook HT, Pickering MC.
PMID: 34379175
Semin Immunopathol. 2021 Oct;43(5):679-690. doi: 10.1007/s00281-021-00882-9. Epub 2021 Aug 11.

IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important...

Cite
Medjeral-Thomas NR, Cook HT, Pickering MC. Complement activation in IgA nephropathy. Semin Immunopathol. 2021;43(5):679-690doi: 10.1007/s00281-021-00882-9.
Medjeral-Thomas, N. R., Cook, H. T., & Pickering, M. C. (2021). Complement activation in IgA nephropathy. Seminars in immunopathology, 43(5), 679-690. https://doi.org/10.1007/s00281-021-00882-9
Medjeral-Thomas, Nicholas R, et al. "Complement activation in IgA nephropathy." Seminars in immunopathology vol. 43,5 (2021): 679-690. doi: https://doi.org/10.1007/s00281-021-00882-9
Medjeral-Thomas NR, Cook HT, Pickering MC. Complement activation in IgA nephropathy. Semin Immunopathol. 2021 Oct;43(5):679-690. doi: 10.1007/s00281-021-00882-9. Epub 2021 Aug 11. PMID: 34379175; PMCID: PMC8551128.
Copy Download .nbib Format: NLM
Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder.

Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors

Livingston NA, Farmer SL, Mahoney CT, Marx BP, Keane TM.
PMID: 34351175
Psychol Addict Behav. 2021 Aug 05; doi: 10.1037/adb0000736. Epub 2021 Aug 05.

OBJECTIVE: Cannabis use disorder (CUD) is the most common non-alcohol related substance use disorder (SUD) in the United States and is especially prevalent among returning veterans. The long-term mental health correlates of CUD remain unknown, which is significant given...

Cite
Livingston NA, Farmer SL, Mahoney CT, et al. Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychol Addict Behav. 2021;doi: 10.1037/adb0000736.
Livingston, N. A., Farmer, S. L., Mahoney, C. T., Marx, B. P., & Keane, T. M. (2021). Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, . https://doi.org/10.1037/adb0000736
Livingston, Nicholas A, et al. "Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder." Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors vol. (2021). doi: https://doi.org/10.1037/adb0000736
Livingston NA, Farmer SL, Mahoney CT, Marx BP, Keane TM. Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychol Addict Behav. 2021 Aug 05; doi: 10.1037/adb0000736. Epub 2021 Aug 05. PMID: 34351175.
Copy Download .nbib Format: NLM
The buffer gas beam: an intense, cold, and slow source for atoms and molecules.

Chemical reviews

Hutzler NR, Lu HI, Doyle JM.
PMID: 22571401
Chem Rev. 2012 Sep 12;112(9):4803-27. doi: 10.1021/cr200362u. Epub 2012 May 09.

No abstract available.

Cite
Hutzler NR, Lu HI, Doyle JM. The buffer gas beam: an intense, cold, and slow source for atoms and molecules. Chem Rev. 2012;112(9):4803-27doi: 10.1021/cr200362u.
Hutzler, N. R., Lu, H. I., & Doyle, J. M. (2012). The buffer gas beam: an intense, cold, and slow source for atoms and molecules. Chemical reviews, 112(9), 4803-27. https://doi.org/10.1021/cr200362u
Hutzler, Nicholas R, et al. "The buffer gas beam: an intense, cold, and slow source for atoms and molecules." Chemical reviews vol. 112,9 (2012): 4803-27. doi: https://doi.org/10.1021/cr200362u
Hutzler NR, Lu HI, Doyle JM. The buffer gas beam: an intense, cold, and slow source for atoms and molecules. Chem Rev. 2012 Sep 12;112(9):4803-27. doi: 10.1021/cr200362u. Epub 2012 May 09. PMID: 22571401.
Copy Download .nbib Format: NLM
The costs of developing treatments for Alzheimer's disease: A retrospective exploration.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E.
PMID: 34581499
Alzheimers Dement. 2021 Sep 28; doi: 10.1002/alz.12450. Epub 2021 Sep 28.

INTRODUCTION: With the exception of the recent accelerated approval of aducanumab, in over 26 years of research and development (R&D) investment in Alzheimer's disease (AD), only five novel drugs-all for symptomatic treatment only-have reached FDA approval. Here, we estimate...

Cite
Cummings JL, Goldman DP, Simmons-Stern NR, et al. The costs of developing treatments for Alzheimer's disease: A retrospective exploration. Alzheimers Dement. 2021;doi: 10.1002/alz.12450.
Cummings, J. L., Goldman, D. P., Simmons-Stern, N. R., & Ponton, E. (2021). The costs of developing treatments for Alzheimer's disease: A retrospective exploration. Alzheimer's & dementia : the journal of the Alzheimer's Association, . https://doi.org/10.1002/alz.12450
Cummings, Jeffrey L, et al. "The costs of developing treatments for Alzheimer's disease: A retrospective exploration." Alzheimer's & dementia : the journal of the Alzheimer's Association vol. (2021). doi: https://doi.org/10.1002/alz.12450
Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer's disease: A retrospective exploration. Alzheimers Dement. 2021 Sep 28; doi: 10.1002/alz.12450. Epub 2021 Sep 28. PMID: 34581499.
Copy Download .nbib Format: NLM
Left atrial appendage thrombus and cerebrovascular events post-transcatheter aortic valve implantation.

European heart journal. Cardiovascular Imaging

van Wiechen MP, Faure ME, Hokken TW, Ooms JF, de Ronde-Tillmans MJ, Hirsch A, Daemen J, de Jaegere PP, Budde RPJ, Van Mieghem NM.
PMID: 34322706
Eur Heart J Cardiovasc Imaging. 2021 Jul 28; doi: 10.1093/ehjci/jeab139. Epub 2021 Jul 28.

AIMS: To elucidate the frequency and clinical impact of left atrial appendage thrombus (LAAT) in patients set for transcatheter aortic valve implantation (TAVI).METHODS AND RESULTS: All patients undergoing TAVI between January 2014 and June 2020 with analysable multislice computed...

Cite
van Wiechen MP, Faure ME, Hokken TW, et al. Left atrial appendage thrombus and cerebrovascular events post-transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2021;doi: 10.1093/ehjci/jeab139.
van Wiechen, M. P., Faure, M. E., Hokken, T. W., Ooms, J. F., de Ronde-Tillmans, M. J., Hirsch, A., Daemen, J., de Jaegere, P. P., Budde, R. P. J., & Van Mieghem, N. M. (2021). Left atrial appendage thrombus and cerebrovascular events post-transcatheter aortic valve implantation. European heart journal. Cardiovascular Imaging, . https://doi.org/10.1093/ehjci/jeab139
van Wiechen, Maarten P, et al. "Left atrial appendage thrombus and cerebrovascular events post-transcatheter aortic valve implantation." European heart journal. Cardiovascular Imaging vol. (2021). doi: https://doi.org/10.1093/ehjci/jeab139
van Wiechen MP, Faure ME, Hokken TW, Ooms JF, de Ronde-Tillmans MJ, Hirsch A, Daemen J, de Jaegere PP, Budde RPJ, Van Mieghem NM. Left atrial appendage thrombus and cerebrovascular events post-transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2021 Jul 28; doi: 10.1093/ehjci/jeab139. Epub 2021 Jul 28. PMID: 34322706.
Copy Download .nbib Format: NLM
Risk factors for type 2 MI: the usual suspects or guilt by association?.

European heart journal

O'Donoghue ML, Marston NA.
PMID: 34599595
Eur Heart J. 2022 Jan 13;43(2):136-137. doi: 10.1093/eurheartj/ehab707.

No abstract available.

Cite
O'Donoghue ML, Marston NA. Risk factors for type 2 MI: the usual suspects or guilt by association?. Eur Heart J. 2022;43(2):136-137doi: 10.1093/eurheartj/ehab707.
O'Donoghue, M. L., & Marston, N. A. (2022). Risk factors for type 2 MI: the usual suspects or guilt by association?. European heart journal, 43(2), 136-137. https://doi.org/10.1093/eurheartj/ehab707
O'Donoghue, Michelle L, and Marston, Nicholas A. "Risk factors for type 2 MI: the usual suspects or guilt by association?." European heart journal vol. 43,2 (2022): 136-137. doi: https://doi.org/10.1093/eurheartj/ehab707
O'Donoghue ML, Marston NA. Risk factors for type 2 MI: the usual suspects or guilt by association?. Eur Heart J. 2022 Jan 13;43(2):136-137. doi: 10.1093/eurheartj/ehab707. PMID: 34599595.
Copy Download .nbib Format: NLM
Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Weber DC, Frick S, Gurtner K, Matuschek C, Harrabi SB, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber NU, Obrecht D, Rutkowski S, Timmermann B, Kortmann RD.
PMID: 34351451
Strahlenther Onkol. 2021 Aug 05; doi: 10.1007/s00066-021-01822-0. Epub 2021 Aug 05.

PURPOSE: In Germany, Austria, and Switzerland, pretreatment radiotherapy quality control (RT-QC) for tumor bed boost (TB) in non-metastatic medulloblastoma (MB) was not mandatory but was recommended for patients enrolled in the SIOP PNET5 MB trial between 2014 and 2018....

Cite
Dietzsch S, Braesigk A, Seidel C, et al. Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlenther Onkol. 2021;doi: 10.1007/s00066-021-01822-0.
Dietzsch, S., Braesigk, A., Seidel, C., Remmele, J., Kitzing, R., Schlender, T., Mynarek, M., Geismar, D., Jablonska, K., Schwarz, R., Pazos, M., Weber, D. C., Frick, S., Gurtner, K., Matuschek, C., Harrabi, S. B., Glück, A., Lewitzki, V., Dieckmann, K., Benesch, M., Gerber, N. U., Obrecht, D., Rutkowski, S., Timmermann, B., & Kortmann, R. D. (2021). Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], . https://doi.org/10.1007/s00066-021-01822-0
Dietzsch, Stefan, et al. "Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial." Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] vol. (2021). doi: https://doi.org/10.1007/s00066-021-01822-0
Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Weber DC, Frick S, Gurtner K, Matuschek C, Harrabi SB, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber NU, Obrecht D, Rutkowski S, Timmermann B, Kortmann RD. Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlenther Onkol. 2021 Aug 05; doi: 10.1007/s00066-021-01822-0. Epub 2021 Aug 05. PMID: 34351451.
Copy Download .nbib Format: NLM
Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy.

Circulation

Marston NA, Oyama K, Jarolim P, Tang M, Sever PS, Keech AC, Lira Pineda A, Wang H, Giugliano RP, Sabatine MS, Morrow DA.
PMID: 34279993
Circulation. 2021 Jul 20;144(3):249-251. doi: 10.1161/CIRCULATIONAHA.121.054663. Epub 2021 Jul 19.

No abstract available.

Cite
Marston NA, Oyama K, Jarolim P, et al. Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation. 2021;144(3):249-251doi: 10.1161/CIRCULATIONAHA.121.054663.
Marston, N. A., Oyama, K., Jarolim, P., Tang, M., Sever, P. S., Keech, A. C., Lira Pineda, A., Wang, H., Giugliano, R. P., Sabatine, M. S., & Morrow, D. A. (2021). Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation, 144(3), 249-251. https://doi.org/10.1161/CIRCULATIONAHA.121.054663
Marston, Nicholas A, et al. "Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy." Circulation vol. 144,3 (2021): 249-251. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.054663
Marston NA, Oyama K, Jarolim P, Tang M, Sever PS, Keech AC, Lira Pineda A, Wang H, Giugliano RP, Sabatine MS, Morrow DA. Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation. 2021 Jul 20;144(3):249-251. doi: 10.1161/CIRCULATIONAHA.121.054663. Epub 2021 Jul 19. PMID: 34279993; PMCID: PMC8442603.
Copy Download .nbib Format: NLM
Showing 5905 to 5914 of 5914 entries